PRECYCLE: Multicenter, Randomized Phase IV Intergroup Trial to Evaluate the Impact of eHealth-based Patient Reported Outcome (PRO) Assessment on Quality of Life in Patients With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Treated With Palbociclib and an Aromatase Inhibitor- or Palbociclib and Fulvestrant
Phase of Trial: Phase IV
Latest Information Update: 29 Mar 2019
Price : $35 *
At a glance
- Drugs Palbociclib (Primary) ; Anastrozole; Exemestane; Fulvestrant; Letrozole
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms PRECYCLE
- 22 Mar 2019 Planned End Date changed from 31 Dec 2023 to 31 Mar 2025.
- 22 Mar 2019 Planned primary completion date changed from 30 Jun 2021 to 31 Dec 2024.
- 31 Aug 2018 Biomarkers information updated